Bone Biologics announces $5.75M funding for bone graft substitute development project

Bone Biologics has just announced the completion of a $5.75 funding venture in collaboration with Musculoskeletal Transplant Foundation, OrthoFix Holdings, Inc. and Hankey Capital, LLC. The proceeds will be geared toward further development and synthesis of a potential bone graft substitute product focused first on bone regeneration in spinal fusion procedures.
“We are pleased with the completion of this round of funding in a challenging investment environment which will allow the company to further execute on its development strategy,” said Steve La Neve, CEO and President of Bone Biologics. “The confidence that these equity investors continue to show in our technology platform, the management team and the professional partners we have assembled is encouraging.”
Read more:
Bone Biologics completes $5.75 Million round of financing (Medical Design and Outsourcing)
Bone Biologics Completes $5.75 Million Round Of Financing (OrthoSpineNews)
Bone Biologics closes $5.8m round (Mass Device)